Viking Therapeutics' New Weight Loss Drug Shows Promising Trial Results

The drug, VK2735, outperforms competitors and could revolutionize obesity and diabetes treatment, though commercial availability remains years away.

Viking Therapeutics introduces VK2735, a promising weight loss drug, showing significant results in a mid-stage trial.
VK2735 outperforms existing treatments from Eli Lilly and Novo Nordisk, with participants losing nearly 15% of their body weight.
The drug mimics two gut hormones, potentially offering a more effective solution for obesity and diabetes management.
Viking plans to meet with the FDA to discuss next steps, but commercial availability could still be years away.
Shares of Viking surged following the trial results, highlighting the market's optimism for the new treatment.